AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02320279 — intervention group
Intervention type: DEVICE
Intervention: Fetal Heart Rate Monitor
Description: Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
Study NCT00513851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930
Description: Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
Study NCT01999998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02441127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser group
Description: the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
Study NCT02441127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel control group
Description: In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
Study NCT00513851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930
Description: Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
Study NCT03996603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens Cream
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
Study NCT04175496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Cake
Description: Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
Study NCT04175496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snacks with Cheese
Description: Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
Study NCT04175496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spicy Crackers
Description: Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
Study NCT04175496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution First Repeat
Description: The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
Study NCT04175496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution Second Repeat
Description: The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
Study NCT01836835 — intervention group
Intervention type: OTHER
Intervention: Pregnancy Unique Questionnaire of Emesis (PUQE)
Description: For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
Study NCT01836835 — intervention group
Intervention type: OTHER
Intervention: 24 hours self-reported nutritional intake form
Description: A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
Study NCT02145975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
Study NCT02145975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
Study NCT03430375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alternating air wheelchair cushion
Description: The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
Study NCT01712867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 acid ethyl esters
Description: 4 capsules/day for 12 weeks
Study NCT01712867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytosterol esters of omega-3
Description: 4 capsules/day for 12 weeks
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
Description: One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
Description: One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT01290679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA - Hypotension
Description: Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1. Give 200 mL Fluid Bolus~2. If not successful, give ephedrine 5 mg bolus~3. Repeat from 1.) if even is not resolved after 3.)
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIVA - Hypotension
Description: Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1. Give 200 mL Fluid Bolus~2. If not successful, give ephedrine 5 mg bolus~3. Repeat from 1.) if even is not resolved after 3.)
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA - Hypertension
Description: Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIVA - Hypertension
Description: Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA - Bradycardia
Description: Defined as: Heart rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIVA - Bradycardia
Description: Defined as: Heart rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA - Tachycardia
Description: Defined as: Heart Rate > 90 beats/min~1. If associated with normal NIBP (MAP > 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~2. If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol.
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIVA - Tachycardia
Description: Defined as: Heart Rate > 90 beats/min~1. If associated with normal NIBP (MAP > 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~2. If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol.
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INH - Hypotension
Description: Defined as: MAP \< 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. give a 200 ml fluid bolus (crystalloid).~2. If not successful, give ephedrine 5 mg bolus.~3. If not successful decrease volatile by 0.1 MAC.~4. Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INH - Hypertension
Description: Defined as: SBP > 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. increase Sevoflurane by 0.1 MAC~2. If not successful after 3 minutes (SBP >130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~3. If still not successful (SBP >130% of baseline), Labetolol 5mg IV will be administered.
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INH - Bradycardia
Description: Defined as: Heart Rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate
Study NCT01942356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INH - Tachycardia
Description: Defined as: Heart rate > 90 beats/min~1. if associated with normal NIBP (MAP > 70% of baseline and SBP \<130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~2. If associated with hypertension (SBP >130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~3. If associated with hypotension (MAP \< 70% of baseline) : proceed with the management of the hypotension during maintenance protocol.
Study NCT03507764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the treadmill workstation at work
Description: During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions.
Study NCT00993343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus/tacrolimus
Description: Standard GVHD prophylaxis
Study NCT00993343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine/methotrexate
Description: Standard GVHD prophylaxis
Study NCT01720498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The effect site concentration of remifentanil
Study NCT03613649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
Study NCT03613649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
Study NCT03613649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
Study NCT03814720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.
Study NCT04392128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Description: Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
Study NCT04392128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 MG Oral Capsule
Description: Azithromycin is amacrolide antibiotic.
Study NCT04531163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: (NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Study NCT03430375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static air cushion
Description: The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
Study NCT02470195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: workshop
Description: workshop for procedural simulation for education in difficult airway situation
Study NCT00226720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient detoxification program
Description: Outpatient detoxification program
Study NCT00226720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient detoxification program
Description: Outpatient detoxification program
Study NCT03473782 — intervention group
Intervention type: OTHER
Intervention: Voiding Diary
Description: A log kept by each patient to record frequency and volume of urine output and fluid input.
Study NCT01828593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
Study NCT03473782 — intervention group
Intervention type: OTHER
Intervention: Urodynamics Correlation Study
Description: Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
Study NCT04392128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
Study NCT04392128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo of Azithromycin capsules.
Study NCT03662191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: bioavailability study
Study NCT03377270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Swallow Training
Description: Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
Study NCT03546036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted metal chain blanket
Description: Use of a weighted metal chain blanket of 8 kg
Study NCT03546036 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control plastic chain blanket
Description: A blanket with light plastic chains
Study NCT00993187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC
Description: Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
Study NCT00993187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Glimepiride
Description: Glimepiride tablet orally up to 6 mg daily for 30 Weeks
Study NCT00993187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to Sitagliptin/Metformin FDC
Description: Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
Study NCT00993187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to glimepiride
Description: Matching placebo to glimepiride tablet orally daily for 30 weeks
Study NCT05133895 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab monotherapy
Description: intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
Study NCT01173809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
Study NCT01173809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
Study NCT02496026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS plus wrist robot therapy
Description: Patients receive robotic rehabilitation session while tDCS stimulator is switched on
Study NCT02496026 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS plus wrist robot therapy
Description: Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
Study NCT01828593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01624129 — intervention group
Intervention type: DRUG
Intervention: Fluticasone
Description: Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
Study NCT03225677 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw and muscle biopsy
Description: One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.